

Thursday, December 8, 2022

17:45 – 18:45 CET

Room A, Palexpo • Geneva, Switzerland

Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC

AGENDA


- I. Welcome & Introductions
– **Solange Peters, MD, PhD**
- II. Identification of NSCLC Biomarkers and Associated Serum and Immunohistochemistry Testing – **Hossein Borghaei, DO, MS**
- III. Clinical Trial Review for Biomarker-Driven Targeted Therapeutics – **Natasha Leighl, MD**
- IV. The Role of CEACAM5-Targeted Therapeutics to Improve Outcomes in Patients with CEA-Positive NSCLC – **David Planchard, MD**
- V. Faculty Panel Discussion – **All Faculty**

CHAIR



Solange Peters,
MD, PhD

FACULTY



Hossein Borghaei,
DO, MS



Natasha B. Leighl,
BSc, MSc, MD



David Planchard,
MD, PhD

CREDIT DESIGNATION STATEMENTS

AcademicCME designates this live material for a maximum of 1.0 European CME Credit® (ECMECs). AcademicCME designates this live material for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Sanofi.